VitaDX is once again supported by BPI France in the amount of 450k€.
Monday January 9th, 2017
Thursday January 5th, 2017
VitaDX launches today its first clinical trial VisioCyt 1. This multicentric study on 1300 patients aims to evaluate the diagnostic performances of the VisioCyt® test.
Tuesday December 20th, 2016
VitaDX is one of the top 100 medical technology startups, according to Innovation Review magazine.
Wednesday November 23rd, 2016
VitaDX and EVOSCIENCES enter into a partnership to facilitate access to the equipment required for the implementation of the VisioCyt® solution.